Peptide-based drug design: Here and now

Methods in Molecular Biology

Volumn 494, Issue , 2008, Pages 1-8

  Otvos Jr , Laszlo ^a  

^a TEMPLE UNIVERSITY   (United States)

Author keywords

Backbone; Design; Nonnatural amino acids; Pharmacology; Recognition; Stability; Toxicity

Indexed keywords

EID: 84934444542     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-59745-419-3_1     Document Type: Review

References (31)

1. Loffet, A. (2002) Peptides as drugs: Is there a market? J. Pept. Sci. 8, 1-7.
2. Ryser, H.J., and Fluckiger, R. (2005) Progress in targeting HIV-1 entry. Drug Discov. Today 10, 1085-1094.
3. Kazmierski, W.M., Kenakin, T.P., and Gudmundsson, K.S. (2006) Peptide, peptidomimetic and small molecule drug discovery targeting HIV-1 host-cell attachment and entry through gp120, gp41, CCR5 and CXCR4. Chem. Biol. Drug Des. 67, 13-26.
4. Mack, M., Luckow, B., Nelson, P.J., et al. (1998) Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J. Exp. Med. 187, 1215-1224.
5. Hartley, O., Gaertner, H., Wilken, J., et al. (2004) Medicinal chemistry applied to a synthetic protein: Development of highly potent HIV entry inhibitors. Proc. Natl. Acad. Sci. USA 101, 16460-16465.
6. Powell, M.F., Stewart, T., Otvos, L., Jr., et al. (1993) Peptide stability in drug development. II. Effect of single amino acid substitution and glycosylation on peptide reactivity in human serum. Pharmacol. Res. 10, 1268-1273.
7. Polt, R., Porreca, F., Szabo, L Z., et al. (1994). Glycopeptide enkephalin analogues produce analgesia in mice; evidence for penetration of the blood-brain barrier. Proc. Natl. Acad. Sci. USA 91, 7114-7118.
8. Egleton, R.D., Mitchell, S.A., Huber, J.D., et al. (2000) Improved bioavailability to the brain of glycosylated Met-enkephalin analogs. Brain Res. 881, 37-46.
9. Otvos, L., Jr., Cudic, M., Chua, B.Y., Deliyannis, G., and Jackson, D.C. (2004) An insect antibacterial peptide-based drug delivery system. Mol. Pharmaceut. 1, 220-232.
10. Josserand, V., Pelerin, H., de Bruin, B., et al. (2006) Evaluation of drug penetration into the brain: a double study by in vivo imaging with positron emission tomography and using an in vitro model of the human blood-brain barrier. J. Pharmacol. Exp. Ther. 316, 79-86.
11. Werle, M. (2006) Innovations in oral peptide delivery. Future Drug Deliver. 39-40.
12. Brogden, K.A. (2005) Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol. 3, 238-250.
13. Zasloff, M. (2002) Antimicrobial peptides of multicellular organisms. Nature 415, 389-395.
14. Cudic, M., Lockatell, C.V., Johnson, D.E., and Otvos, L., Jr. (2003) In vitro and in vivo activity of antibacterial peptide analogs against uropathogens. Peptides 24, 807-820.
15. Otvos, L., Jr. (2005) Antibacterial peptides and proteins with multiple cellular targets. J. Pept. Sci. 11, 697-706.
16. Bray, B.L. (2003) Large-scale manufacture of peptide therapeutics by chemical synthesis. Nat. Rev. Drug Discovery 2, 587-593.
17. Garber, K. (2005) Peptide leads new class of chronic pain drugs. Nat. Biotechnol. 23, 399.
18. Meloen, R., Timmerman, P., and Langedijk, H. (2004) Bioactive peptides based on diversity libraries, supramolecular chemistry and rational design; A class of peptide drugs. Introduction. Mol. Diversity 8, 57-59.
19. Muderspach, L., Wilczynski, S., Roman, L., et al. (2000) A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin. Cancer Res. 6, 3406-3416.
20. Agdeppa, E.D. (2004) Rational design for peptide drugs. J. Nucl. Med. 47, 22N-24N.
21. Backer, M.V., Levashova, Z., Patel, V., et al. (2007) Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes. Nat. Med. 13, 504-509.
22. Arai, H., Lee, V.M.-Y., Otvos, L., Jr., et al. (1990) Defined neurofilament, tau and beta-amyloid precursor protein epitopes distinguish Alzheimer from non-Alzheimer senile plaques. Proc. Natl. Acad. Sci. USA 87, 2249-2253.
23. Hoffmann, R., Lee, V.M.Y., Leight, S., Varga, I., and Otvos, L., Jr. (1997) Unique Alzheimer's disease paired helical filament specific epitopes involve double phosphorylation at specific sites. Biochemistry 36, 8114-8124.
24. Adessi, C., Frossard, M-J., Boissard, C., et al. (2003). Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer's disease. J. Biol. Chem. 278, 13905-13991.
25. Kotha, S., and Lahiri, K. (2005) Post-treatment assembly modifications by chemical methods. Curr. Med. Chem. 12, 849-875.
26. Sehgal, A. (2002) Recent development in peptide-based cancer therapeutics. Curr. Opin. Drug Discov. Devel. 5, 245-250.
27. Borghouts, C., Kunz, C., and Groner, B. (2005) Current strategies for the development of peptide-based anti-cancer therapeutics. J. Pept. Sci. 11, 713-726.
28. Bruns, C., Lewis, I., Briner, U., Meno-Tetang, G., and Weckbecker, G. (2002) SOM230: a novel somatostatin petidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur. J. Endocrin. 146, 707-716.
29. Fedele, M., DeMartino, I., Pivonello, R., et al. (2007) SOM230, a new somatostatin analogue, is highly effective in the therapy of growth hormone/prolactin-secreting pituitary adenomas. Clin. Cancer Res. 13, 2738-2744.
30. Phan, J., Shi, Z-D., Burke, T.R., Jr., and Waugh, D.S. (2005) Crsytal structures of a high-affinity macrocyclic peptide mimetic complex with the Grb2 SH2 domain. J. Mol. Biol. 353, 104-115.
31. a and E-selectin in metastasis assessed with peptide antagonist. Peptides 23, 999-1010.